MoonLake Immunotherapeutics

NasdaqCM MLTX

MoonLake Immunotherapeutics Receivables for the year ending December 31, 2023: USD 1.06 M

MoonLake Immunotherapeutics Receivables is USD 1.06 M for the year ending December 31, 2023, a 386.74% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

MoonLake Immunotherapeutics Receivables for the year ending December 31, 2022 was USD 217.13 K, a 45.95% change year over year.
MoonLake Immunotherapeutics Receivables for the year ending December 31, 2021 was USD 148.77 K.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

NasdaqCM: MLTX

MoonLake Immunotherapeutics

CEO	Dr. Jorge Santos da Silva
IPO Date	Oct. 20, 2020
Location	Switzerland
Headquarters	Dorfstrasse 29
Employees	50
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Key trends

Past 5 years